Gordon, K., Warren, R. B., Gottlieb, A. B., Blauvelt, A., Tha?i, D., Poulin, Y., Boehnlein, M., Brock, F., Arendt, C. and Reich, K. (2020) “Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)”, SKIN The Journal of Cutaneous Medicine, 4(5), p. s45. doi: 10.25251/skin.4.supp.45.